Invivyd, Inc. (Nasdaq: IVVD) has commenced an underwritten public offering of shares of its common stock.
The company intends to grant the underwriters an option to purchase additional shares.
The offering is subject to market conditions, and the net proceeds will be used for various purposes including research and development.
Public Offering Commencement
Invivyd initiated an underwritten public offering of common stock.
Underwriter Option
Underwriters have the option to purchase up to an additional 15% of the shares.
Use of Net Proceeds
The company plans to utilize the net proceeds for clinical programs and research activities.
- Invivyd's public offering demonstrates its commitment to advancing its clinical programs.
- The underwriter's involvement indicates confidence in the company's potential.
- The utilization of funds for research highlights Invivyd's dedication to scientific advancements.
Invivyd's proposed public offering marks a strategic move to secure funding for its ongoing initiatives, showcasing its dedication to innovative biopharmaceutical solutions.